Plexxikon Inc. (Plexxikon)

Oncology Corporate Profile

HQ Location

91 Bolivar Drive
Berkeley, CA 94710

Company Description

Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage programs in a number of therapeutic areas and disease indications. Plexxikon's platform enables the design of highly selective and targeted medicines, supporting the company's broader strategy to develop personalized medicines.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PLX3397CSF1 inhibitorTenosynovial giant cell tumor (TGCT)III
PLX3397 (eribulin)CSF1 inhibitorBreast cancerII
PLX3397 (+ radiation therapy and temozolomide)CSF1 inhibitorGlioblastoma Multiforme (GBM)II
PLX3397 (+ paclitaxel)CSF1 inhibitorNeoadjuvant Breast cancerII
PLX3397 (+ pembrolizumab)CSF1 inhibitorMelanomaI
PLX3397 (+ pembrolizumab)CSF1 inhibitorOvarian cancerI
PLX3397 (+ pembrolizumab)CSF1 inhibitorVarious cancer typesI
PLX7486CSF1 inhibitorPancreatic cancer
PLX9486CSF1 inhibitorGastrointestinal Stromal Tumors (GIST)Preclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display